Thromboxane b2

Thromboxane b2 is a lipid of Fatty Acyls (FA) class. Thromboxane b2 is associated with abnormalities such as endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia and Thrombocytosis. The involved functions are known as Platelet Activation, Excretory function, Anabolism, Inflammation and mRNA Expression. Thromboxane b2 often locates in Endothelium, Hepatic and Microsomes, Liver. The associated genes with Thromboxane b2 are PTGS2 gene, prothrombin fragment 2 and CCL14 wt Allele.

Cross Reference

Introduction

To understand associated biological information of Thromboxane b2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Thromboxane b2?

Thromboxane b2 is suspected in endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia, Thrombocytosis, Acute Coronary Syndrome and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Thromboxane b2

MeSH term MeSH ID Detail
Acute Kidney Injury D058186 34 associated lipids
Airway Remodeling D056151 3 associated lipids
Acute Coronary Syndrome D054058 11 associated lipids
Hypoalphalipoproteinemias D052456 5 associated lipids
Atherosclerosis D050197 85 associated lipids
Dyslipidemias D050171 7 associated lipids
Cholecystitis, Acute D041881 1 associated lipids
Pulmonary Disease, Chronic Obstructive D029424 16 associated lipids
Metabolic Syndrome D024821 44 associated lipids
Coronary Stenosis D023921 6 associated lipids
Per page 10 20 50 100 | Total 293

PubChem Associated disorders and diseases

What pathways are associated with Thromboxane b2

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Thromboxane b2?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Thromboxane b2?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

What genes are associated with Thromboxane b2?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with Thromboxane b2

Download all related citations
Per page 10 20 50 100 | Total 6367
Authors Title Published Journal PubMed Link
Jiang Z et al. [The changes of thromboxane B2 (TXB2) and 6-keto-prostaglandin F1 alpha(6-keto-PGF1 alpha) in the lungs of rats drowned in hypothermic-sea-water]. 2002 Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi pmid:14694611
Kawata K et al. The effects of a selective cyclooxygenase-2 inhibitor on small bowel ischemia-reperfusion injury. 2003 Nov-Dec Hepatogastroenterology pmid:14696445
Ersöz G et al. Effect of sodium selenite treatment on platelet aggregation of streptozotocin-induced diabetic rats. 2003 Thromb. Res. pmid:14698654
Al-Madaney MM et al. Effects of lipid-esterified conjugated linoleic acid isomers on platelet function: evidence for stimulation of platelet phospholipase activity. 2003 Biochim. Biophys. Acta pmid:14729070
Wurtz MM et al. Enhanced microvascular permeability of PMA-induced acute lung injury is not mediated by cyclooxygenase products. 1992 J. Appl. Physiol. pmid:1474095
Scott G et al. Lumiracoxib: pharmacokinetic and pharmacodynamic profile when coadministered with fluconazole in healthy subjects. 2004 J Clin Pharmacol pmid:14747429
Horiuchi H et al. 1,25-Dihydroxyvitamin D3 inhibits thromboxane release from activated macrophages. 1992 Res. Commun. Chem. Pathol. Pharmacol. pmid:1475528
Cotter G et al. Lack of aspirin effect: aspirin resistance or resistance to taking aspirin? 2004 Am. Heart J. pmid:14760328
Horani MH et al. Cyclooxygenase inhibition is associated with downregulation of apolipoprotein AI promoter activity in cultured hepatoma cell line HepG2. 2004 Metab. Clin. Exp. pmid:14767868
Hayball PJ et al. Enantioselective pharmacodynamics of the nonsteroidal antiinflammatory drug ketoprofen: in vitro inhibition of human platelet cyclooxygenase activity. 1992 Chirality pmid:1476858
Peck OM et al. Staphylococcus aureus and lipopolysaccharide induce homologous tolerance but heterologous priming: role of interferon-gamma. 2004 Shock pmid:14770039
Zhu PJ [Therapeutic changes in nephrotic syndrome treated with yiqi huoxue jiedu decoction and corticosteroid]. 1992 Zhongguo Zhong Xi Yi Jie He Za Zhi pmid:1477504
Chetty N and Naran NH Platelet hyperreactivity in hyperlipidaemia with specific reference to platelet lipids and fatty acid composition. 1992 Clin. Chim. Acta pmid:1477981
Ylikorkala O and Viinikka L The role of prostaglandins in obstetrical disorders. 1992 Baillieres Clin Obstet Gynaecol pmid:1477999
Katoh K Possible relevance of lipid peroxidation and thromboxane production to the initiation and/or evolution of microangiopathy in non-hyperlipidemic type 2 diabetes mellitus. 1992 Diabetes Res. Clin. Pract. pmid:1478157
Tóth L et al. Elevated levels of plasma and urine beta-thromboglobulin or thromboxane-B2 as markers of real platelet hyperactivation in diabetic nephropathy. 1992 Haemostasis pmid:1478544
Truog WE et al. Acute changes in vasoactive lipid mediators in experimental hyaline membrane disease. 1992 Respir Physiol pmid:1480845
Mozes T et al. Lethal and non-lethal course of endotoxic shock is determined by interactions between tumor necrosis factor, platelet activating factor and eicosanoids. 1992 Pathol. Biol. pmid:1484741
Sochanowicz B and Dancewicz AM Thromboxane increase in irradiated animals is caused by stimulation of cyclooxygenase activity. 1992 Acta Biochim. Pol. pmid:1485488
Desideri N et al. Synthesis of some guanylhydrazones and imidazolinylhydrazones as thromboxane-synthase and platelet aggregation inhibitors. 1992 Arch. Pharm. (Weinheim) pmid:1489254
Ratzmann KP et al. Improvement of metabolic control and changes of fatty acid composition do not alter platelet aggregability and thromboxane production in type 2 diabetes mellitus. 1992 Horm. Metab. Res. Suppl. pmid:1490671
Koch T et al. Alterations of filtration coefficients in pulmonary edema of different pathogenesis. 1992 J. Appl. Physiol. pmid:1490949
Longworth KE et al. Development of pulmonary intravascular macrophage function in newborn lambs. 1992 J. Appl. Physiol. pmid:1490977
Abbakumov VV et al. [The prostacyclin-thromboxane system and platelet hemostasis following aortocoronary bypass with an uncomplicated postoperative course]. 1992 Sep-Dec Anesteziol Reanimatol pmid:1492691
Nakayama DK et al. Relation between arterial hypoxemia and plasma eicosanoids in neonates with congenital diaphragmatic hernia. 1992 J. Surg. Res. pmid:1494296
Bruno A et al. Serial urinary 11-dehydrothromboxane B2, aspirin dose, and vascular events in blacks after recent cerebral infarction. 2004 Stroke pmid:14963281
Kwak SH et al. Effects of propofol on endotoxin-induced acute lung injury in rabbit. 2004 J. Korean Med. Sci. pmid:14966342
Urade M et al. Changes of thromboxane B2 level in experimental orthotopic liver transplantation in swines--the effect of warm ischemia and thromboxane A2 synthetase inhibition. 1992 Transplant. Proc. pmid:1496677
Noris M et al. Renal prostacyclin biosynthesis is reduced in children with hemolytic-uremic syndrome in the context of systemic platelet activation. 1992 Am. J. Kidney Dis. pmid:1496967
Swaim SF et al. Evaluation of the dermal effects of cast padding in coaptation casts on dogs. 1992 Am. J. Vet. Res. pmid:1497201
Tsai CY et al. Proinflammatory cytokines enhance COX-1 gene expression in cultured rat glomerular mesangial cells. 2004 Int. Immunopharmacol. pmid:14975359
Smalling WE et al. Protective effect of pentoxifylline on volume-induced lung injury in newborn piglets. 2004 Biol. Neonate pmid:14981352
Kawada N et al. Possible induction of fatty acid cyclo-oxygenase in lipopolysaccharide-stimulated rat Kupffer cells. 1992 Gastroenterology pmid:1499903
Yugar-Toledo JC et al. Uncontrolled hypertension, uncompensated type II diabetes, and smoking have different patterns of vascular dysfunction. 2004 Chest pmid:15006938
Takashima M et al. [A trial of low-dose aspirin therapy in high-risk pregnancy]. 1992 Nippon Sanka Fujinka Gakkai Zasshi pmid:1500806
Díaz AM et al. Phenylpropanoid glycosides from Scrophularia scorodonia: in vitro anti-inflammatory activity. 2004 Life Sci. pmid:15010262
Li D et al. Diet rich in saturated fat decreases the ratio of thromboxane/prostacyclin in healthy men. 2003 Biomed. Environ. Sci. pmid:15011964
Ikonomidis I et al. Reduction of daily life ischaemia by aspirin in patients with angina: underlying link between thromboxane A2 and macrophage colony stimulating factor. 2004 Heart pmid:15020512
Lassila R and Laustiola KE Cigarette smoking and platelet-vessel wall interactions. 1992 Prostaglandins Leukot. Essent. Fatty Acids pmid:1502254
Uehara Y et al. Abnormal response of urinary eicosanoid system to norepinephrine infusion in patients with essential hypertension. 1992 Prostaglandins Leukot. Essent. Fatty Acids pmid:1502257
Dippel DW et al. What is the lowest dose of aspirin for maximum suppression of in vivo thromboxane production after a transient ischemic attack or ischemic stroke? 2004 Cerebrovasc. Dis. pmid:15026612
Capone ML et al. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. 2004 Circulation pmid:15037526
Jones SB et al. Altered aortic production of 6-keto-prostaglandin F1 alpha from aldosterone-salt hypertensive rats. 1992 May-Jun J. Vasc. Res. pmid:1504198
Rotondo S et al. Licofelone, an inhibitor of cyclooxygenase and 5-lipoxygenase, specifically inhibits cyclooxygenase-1-dependent platelet activation. 2004 Eur. J. Pharmacol. pmid:15044038
Guay J et al. Carrageenan-induced paw edema in rat elicits a predominant prostaglandin E2 (PGE2) response in the central nervous system associated with the induction of microsomal PGE2 synthase-1. 2004 J. Biol. Chem. pmid:15044444
Véricel E et al. Diabetic patients without vascular complications display enhanced basal platelet activation and decreased antioxidant status. 2004 Diabetes pmid:15047620
Dinev D and Andonova M The effect of general anesthesia and abdominal surgery upon plasma thromboxane B concentrations in horses. 2004 Vet Anaesth Analg pmid:15053753
Wang YY et al. Inhibition of platelet aggregation by polyaspartoyl L-arginine and its mechanism. 2004 Acta Pharmacol. Sin. pmid:15066215
Yoshimura T et al. [Urinary 11-dehydrothromboxane B2 and 6-keto-prostaglandin F1 alpha in normal pregnant women and in women complicated with pregnancy-induced hypertension]. 1992 Nippon Sanka Fujinka Gakkai Zasshi pmid:1506726
Park HS et al. Dietary conjugated linoleic acid increases the mRNA ratio of Bax/Bcl-2 in the colonic mucosa of rats. 2004 J. Nutr. Biochem. pmid:15068816